Assessing Safety & PK Profiles of ADCs Against Glioblastoma to Understand Reasons for Observed Toxicity & Explore Mitigation Strategies
- Evaluating toxicity of three EGFR-targeting ADCs with different payloads with results showing bystander activity and premature payload release in the brain microenvironment
- Investigating EGFR-targeting ADCs in glioblastoma PDX models to narrow down best performing toxicity and PK profiles
- Exploring changes in ADC design to optimize bystander activity and therapeutic index against glioblastoma